The execution of molecular genetic tests using DNA of tumor cells obtained from cytologic preparations

Abstract

This article presents the outcomes of implementation of DNA testing in oncology using tumor DNA cells taken from the cytological specimens. DNA attribute of the cytological specimen of 113 patients has been investigated. EGFR gene mutation for the diagnosed pulmonary adenocarcinoma (n=75) has been determined for proper assignment of the target medicines and individual therapy. Mutation has been determined in 10.9% cases. KRAS, BRAF and BRCA1/2 gene mutation has been determined in 38 women suffering from ovarian serous carcinoma. Ovarian low-grade serous carcinoma with KRAS gene mutation has been determined in 71.4 % of the patients. The prognosis for these women is more favourable, as well as for a small portion of the women with BRCA1 gene mutation (14.3 %) from ovarian high-grade serous carcinoma group due to the fact that they are more susceptible to platine medicines. Cytological specimen is valuable material for DNA testing subject to enough number of the tumour cells available.